Skip to Content

AstraZeneca - Seroquel


AstraZeneca - Seroquel

AstraZeneca allegedly engaged in unfair and deceptive practices when it marketed its atypical antipsychotic drug, Seroquel, for treatments that were not approved by FDA (“off-label marketing”). The complaint also alleges AstraZeneca failed to adequately disclose the drug’s potential side effects to health care providers, and withheld negative information contained in scientific studies concerning the safety and efficacy of Seroquel, also in violation of the Tennessee Consumer Protection Act. This was a multistate case.

Press Release

State Court Filings in AstraZeneca - Seroquel

 

This list includes only significant filings and is not intended to be a complete record of the matter.